RB1 and cancer: ECTM- and Δ16ECTM-IgG antibodies purified from immune sera inhibited cancer cell viability mainly by interfering with ERK activation and leading to the reactivation of RB in both trastuzumab-sensitive and -resistant BT-474 cells.